CEVAC CORYMUNE 7K (INACTIVATED VACCINE)

Indications

• Vaccination against infectious diseases
• Diagnosis of allergies
• Cancer immunotherapy
• Autoimmune disease modulation

Dosage

Children: Refer to specific product guidelines as doses can vary based on the antigen and the purpose of administration.

Adults: Refer to specific product guidelines as doses can vary based on the antigen and the purpose of administration.

Mechanism of action

Antigens act by binding to specific receptors on immune cells, such as B cells and T cells. This binding activates these cells, leading to the production of antibodies (in the case of B cells) or cytotoxic responses (in the case of T cells). The recognition of antigens by the immune system involves antigen presentation by Major Histocompatibility Complex (MHC) molecules, which display peptide fragments of the antigen on the surface of antigen-presenting cells.

Pharmacodynamics

The presence of antigens triggers a series of immune responses, including the activation of lymphocytes, cytokine production, and the formation of memory cells. These processes are essential for the body to recognize and mount an effective defense against subsequent exposures to the same antigen, contributing to immunological memory and long-term protection.

Pharmacokinetics

The pharmacokinetics of antigens can vary widely depending on their nature and route of administration. Generally, antigens can be administered via intramuscular, subcutaneous, or intradermal routes. Upon administration, they are processed by antigen-presenting cells, which then migrate to lymph nodes to activate T and B cells. The distribution, metabolism, and elimination of antigens depend on their structure and the immune response they elicit.

Adverse effects

• Local reactions at the injection site
• Systemic allergic reactions
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Monitor for allergic reactions after administration
• Use with caution in individuals with a history of severe allergic reactions
• Consider the patient's immune status before administration

Pregnancy

Consult a healthcare professional before use. The safety of antigens in pregnancy varies depending on the type of antigen and the specific clinical context.

Breast-feeding

Consult a healthcare professional before use. The transfer of antigens into breast milk is variable and depends on the type of antigen.

Storage

Store at recommended temperatures, usually between 2°C and 8°C. Protect from light and do not freeze.

Formulations

• Injectable solutions
• Suspensions
• Lyophilized powders for reconstitution

Dosage

Children: Refer to specific veterinary guidelines or pharmacological references for dosing information, as it varies widely based on the specific drug and condition being treated.

Adults: Refer to specific veterinary guidelines or pharmacological references for dosing information, as it varies widely based on the specific drug and condition being treated.

Mechanism of action

The mechanism of action for avian-related treatments varies widely depending on the specific substance or medication being used. For example, antiviral medications targeting avian influenza viruses may inhibit viral replication by interfering with the viral life cycle, often through mechanisms such as blocking viral entry into host cells or inhibiting viral neuraminidase activity.

Pharmacodynamics

Pharmacodynamics for avian-targeting drugs can include effects on avian physiology, such as modulation of immune response, reduction of viral load, or treatment of bacterial infections. The efficacy and effects depend on the specific condition being treated and the drug's pharmacological profile.

Pharmacokinetics

Pharmacokinetics will differ based on the specific substance being referenced. Typically, this includes absorption, distribution, metabolism, and excretion profiles that are unique to the drug class. In avian species, factors such as species-specific metabolism and physiological differences play crucial roles in how drugs are processed.

Pregnancy

Not enough data available regarding safety in pregnancy. Use with caution and only if the benefits outweigh the risks.

Breast-feeding

Limited data available. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Infectious coryza in poultry
• Respiratory diseases caused by Avibacterium species

Dosage

Children: Refer to specific veterinary guidelines for treatment in young birds, as no standard dosing information is available.

Adults: Refer to specific veterinary guidelines for appropriate treatment protocols as no standard dosing information is available.

Mechanism of action

Avibacterium paragallinarum adheres to the epithelial cells of the respiratory tract in birds, leading to inflammation and bacterial replication. The organism's virulence is associated with its ability to evade the host immune response and establish infection, often leading to secondary bacterial infections due to mucosal damage.

Pharmacodynamics

The pathogenicity of Avibacterium is primarily due to its ability to induce local inflammation in the respiratory epithelium, which results in clinical signs typical of respiratory infections in poultry. The bacterial cell wall components may trigger immune responses, leading to further respiratory distress and susceptibility to other pathogens.

Pharmacokinetics

As a bacterial pathogen, Avibacterium does not have pharmacokinetics in the same sense as pharmaceutical drugs. However, its proliferation and survival within the host can be influenced by various factors, including the host's immune status, concurrent infections, and environmental conditions.

Pregnancy

There is limited data on the use of avibacterium during pregnancy. Consult relevant guidelines before prescribing.

Breast-feeding

Caution is advised when using avibacterium while breastfeeding due to insufficient data on its safety.

Storage

Store at room temperature, away from direct sunlight and moisture. Specific storage conditions may vary depending on the formulation.

Indications

• Acute bronchitis
• Chronic bronchitis
• Bronchiectasis
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to BNF for Children for appropriate dosing based on the child's age, weight, and the severity of the condition.

Adults: Refer to specific treatment guidelines or BNF for dosing recommendations based on the severity of the condition and the type of medication used.

Mechanism of action

In bronchitis, the inflammation leads to hypersecretion of mucus and bronchoconstriction. Treatment often includes bronchodilators to relax airway muscles and anti-inflammatory agents to reduce swelling. In cases of bacterial bronchitis, antibiotics may be used to target the offending pathogens.

Pharmacodynamics

The pharmacodynamics of drugs used in bronchitis focus on reducing inflammation and bronchoconstriction, facilitating easier breathing. Bronchodilators work by stimulating beta-adrenergic receptors to induce bronchodilation, while corticosteroids reduce inflammatory responses in the airways.

Pharmacokinetics

The pharmacokinetics of drugs prescribed for bronchitis vary. For example, bronchodilators are rapidly absorbed and act within minutes, while corticosteroids may take longer to exert their full effects. The distribution of these drugs occurs systemically, with metabolism primarily in the liver and excretion through urine.

Pregnancy

Consult a healthcare professional before use, as safety during pregnancy has not been fully established.

Breast-feeding

Consult a healthcare professional before use, as it is unclear if the drug passes into breast milk.

Storage

Store in a cool, dry place away from direct sunlight.

Dosage

Children: Refer to specific medications used to treat the particular disease for dosing information.

Adults: Refer to specific medications used to treat the particular disease for dosing information.

Mechanism of action

The mechanism of action varies significantly depending on the specific disease in question. For infectious diseases, pathogens may interact with host cells, leading to inflammation, immune response activation, or tissue damage. Chronic diseases often involve complex interactions between genetic factors, lifestyle choices, and environmental influences. For example, in autoimmune diseases, the immune system mistakenly targets healthy cells, leading to inflammation and tissue destruction.

Pharmacodynamics

Pharmacodynamics of disease involves understanding how the disease state affects physiological functions and the body's response to treatment. In infectious diseases, the presence of pathogens can lead to altered immune responses, while chronic diseases may involve changes in metabolic pathways, hormonal balances, or cellular functions. Medications targeting disease processes aim to restore normal function, alleviate symptoms, or eradicate pathogens.

Pharmacokinetics

Pharmacokinetics is not applicable to the term 'disease' as it refers to the movement of drugs within the body, including absorption, distribution, metabolism, and excretion of specific medications used to treat diseases. Each medication will have its own pharmacokinetic profile depending on its chemical properties and the disease being treated.

Indications

• Prevention of postoperative nausea and vomiting
• Treatment of nausea and vomiting
• Premedication for surgical procedures

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations based on the clinical context and patient condition.

Mechanism of action

Droperidol primarily acts as an antagonist at dopamine D2 receptors in the central nervous system. This blockade of dopamine receptors leads to a decrease in nausea and vomiting, as dopamine is a key neurotransmitter involved in these processes. Furthermore, droperidol may also have some affinity for other receptor types, including adrenergic and serotonin receptors, contributing to its sedative and antiemetic effects.

Pharmacodynamics

The pharmacodynamic profile of droperidol includes its ability to reduce the incidence of nausea and vomiting through central action. It can also produce sedation and anxiolytic effects, making it useful in preoperative settings. The onset of action is typically rapid, with effects observed shortly after administration. Droperidol has a dose-dependent relationship, where higher doses may lead to increased sedation and potential extrapyramidal side effects due to its dopamine antagonism.

Pharmacokinetics

Droperidol is well-absorbed after parenteral administration, with peak plasma concentrations occurring within 30 minutes to 1 hour. It is metabolized in the liver, primarily via cytochrome P450 enzymes, and has a relatively short half-life, generally ranging from 1 to 3 hours. Droperidol is excreted mainly in urine as metabolites, with less than 1% of the dose excreted unchanged. The drug's pharmacokinetic profile can be influenced by factors such as age, liver function, and concurrent medications.

Interactions

• droperidol + dopaminereceptor agonists: Severe (decreases effects)
• droperidol + levodopa: Unknown (decreases effects)

Indications

• Salmonella enteritidis infection
• Foodborne illness
• Gastroenteritis

Dosage

Children: Dosage for children should be determined based on weight and severity of symptoms. Refer to pediatric guidelines for specific dosing recommendations.

Adults: Treatment may vary based on the severity of the infection and the susceptibility of the strain to antibiotics. Refer to local guidelines for appropriate therapeutic regimens.

Mechanism of action

Salmonella enteritidis invades the intestinal epithelial cells, leading to inflammation and disruption of the intestinal barrier. It utilizes various virulence factors, including invasion proteins, to facilitate its entry into host cells and evade the host's immune response. The bacteria can also induce apoptosis in host cells, contributing to tissue damage and diarrhea.

Pharmacodynamics

Enteritidis infections provoke an immune response characterized by the activation of neutrophils and macrophages, leading to the release of pro-inflammatory cytokines. This immune response is responsible for the clinical manifestations of the infection, including fever and diarrhea. The inflammatory response can also lead to fluid secretion in the intestines, exacerbating diarrhea.

Pharmacokinetics

As a bacterial pathogen, Enteritidis does not follow traditional pharmacokinetics associated with drugs. Instead, its survival and replication depend on its ability to colonize the gastrointestinal tract and evade host immune mechanisms. Antibiotic treatment, if utilized, would depend on the sensitivity of the strain, with pharmacokinetic considerations being relevant to the chosen antimicrobial agents.

Pregnancy

Safety during pregnancy has not been established. Use only if potential benefit justifies potential risk to the fetus.

Breast-feeding

Caution is advised, as it is not known whether this drug is excreted in human milk.

Storage

Store in a cool, dry place, away from direct light. Maintain at room temperature unless otherwise specified.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Bacterial infections
• Viral infections
• Fungal infections
• Parasitic infections
• Sepsis
• Pneumonia
• Urinary tract infections
• Skin and soft tissue infections

Dosage

Children: Refer to specific drug monographs for dosing information based on the type of infection and child's age and weight.

Adults: Refer to specific drug monographs for dosing information based on the type of infection and pathogen involved.

Mechanism of action

The mechanism of action of antimicrobial agents varies widely depending on the class of drug. For example, antibiotics may inhibit cell wall synthesis, protein synthesis, or nucleic acid synthesis in bacteria. Antivirals often target viral replication processes, while antifungal agents disrupt cell membrane integrity or inhibit essential metabolic pathways in fungi.

Pharmacodynamics

Pharmacodynamics of infectious disease treatments involves understanding the drug's effects on the pathogen, including the minimum inhibitory concentration (MIC) that inhibits bacterial growth, or the time and concentration needed to effectively reduce viral load. The efficacy of the antimicrobial therapy is influenced by factors such as the site of infection, the immune response of the host, and the susceptibility profile of the pathogen.

Pharmacokinetics

Pharmacokinetics of antimicrobial agents encompasses absorption, distribution, metabolism, and excretion. For instance, antibiotics may be well absorbed orally but have variable bioavailability. Distribution can be affected by tissue permeability and protein binding. Metabolism may occur in the liver, and excretion is primarily renal, influencing dosing in patients with renal impairment.

Pregnancy

Consult healthcare professional; safety varies by specific infectious agent and treatment.

Breast-feeding

Consult healthcare professional; safety varies by specific infectious agent and treatment.

Storage

Store in a cool, dry place, away from direct sunlight; specific storage may vary by formulation.

Indications

• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)
• Lymphoblastic lymphoma

Dosage

Children: Refer to specific guidelines as dosing may vary based on protocol and patient response.

Adults: Refer to specific guidelines as dosing may vary based on protocol and patient response.

Mechanism of action

Lasota functions as a recombinant enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. This enzymatic reaction reduces the availability of asparagine in the bloodstream, which is crucial for the survival of lymphoid cells. Tumors, particularly lymphoblastic leukemia cells, are unable to synthesize asparagine due to the lack of asparagine synthetase, making them susceptible to this depletion.

Pharmacodynamics

The pharmacodynamic effects of lasota are centered on its ability to induce asparagine depletion, leading to apoptosis in asparagine-dependent neoplastic cells. The effectiveness of lasota is influenced by the concentration of asparagine in the body and the sensitivity of the tumor to asparagine depletion. The therapeutic window is critical, as excessive depletion can lead to adverse effects.

Pharmacokinetics

Lasota has a unique pharmacokinetic profile characterized by a short half-life and variable distribution in the body. It is administered intravenously and is rapidly distributed to tissues. The elimination of lasota primarily occurs through hydrolysis and is influenced by the patient's body weight and the presence of enzymes in the blood. Due to its enzyme nature, it does not have a traditional clearance mechanism related to liver or kidney function, making dosing adjustments less straightforward.

Pregnancy

There is limited data on the use of lasota during pregnancy. Caution is advised, and it should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether lasota is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Prevention of Newcastle disease in poultry
• Potential oncolytic therapy in cancer treatment

Dosage

Children: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Adults: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Mechanism of action

Newcastle disease virus exerts its effects primarily through the induction of apoptosis in infected cells and the activation of the host immune system. The virus binds to specific receptors on the surface of host cells, facilitating viral entry and replication. It leads to the release of pro-inflammatory cytokines and enhances the anti-tumor immune response in the context of oncolytic therapies.

Pharmacodynamics

The pharmacodynamics of Newcastle disease virus involves its ability to replicate in tumor cells, leading to cell lysis and release of viral progeny that can further infect and destroy adjacent tumor cells. The host's immune system is subsequently activated, enhancing the overall anti-tumor response.

Pharmacokinetics

The pharmacokinetics of Newcastle disease virus is complex, as it involves viral replication and dissemination within the host. Following administration, the virus replicates at the site of infection, with peak viral loads observed at various time points depending on the route of administration and the host's immune status. The virus is typically cleared by the immune system over time, although its persistence can vary based on the type of host cells infected.

Pregnancy

Safety in pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Safety during breastfeeding is not well established. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight and heat. Follow specific storage requirements if available.

Indications

• Chronic respiratory disease in poultry
• Inflammatory processes in avian species
• Systemic infections in birds

Dosage

Children: Refer to veterinary pharmacology resources for pediatric dosing information.

Adults: Refer to clinical guidelines and veterinary pharmacology resources for specific dosing regimens.

Mechanism of action

Paragallinarum adheres to the host's epithelial cells, evading immune responses and causing localized inflammation. The bacterium produces various virulence factors, including adhesins and toxins, which facilitate colonization and tissue damage. These components disrupt normal cellular functions, promoting infection and disease progression.

Pharmacodynamics

The pharmacodynamics of treatments targeting Paragallinarum focus on inhibiting its growth and neutralizing its pathogenic effects. Antibiotics or vaccines may be used to reduce the bacterial load and mitigate the associated inflammatory response. The effectiveness of such treatments often depends on the timing of administration and the specific strain of the bacterium.

Pharmacokinetics

The pharmacokinetics of drugs used against Paragallinarum typically involve absorption after administration, distribution throughout the body, metabolism in the liver, and excretion via urine or feces. The pharmacokinetic profile can vary based on the drug class and the route of administration, influencing the duration and intensity of the therapeutic effect.

Pregnancy

Data on the use of paragallinarum during pregnancy is limited, consult a healthcare provider for guidance.

Breast-feeding

Data on the use of paragallinarum during breastfeeding is limited, consult a healthcare provider for guidance.

Storage

Store at room temperature, protect from light and moisture, and keep out of reach of children.

Indications

• Salmonellosis
• Gastroenteritis
• Typhoid fever
• Paratyphoid fever

Dosage

Children: Refer to appropriate guidelines based on the severity of the infection and local antimicrobial susceptibility patterns.

Adults: Refer to appropriate guidelines based on the severity of the infection and local antimicrobial susceptibility patterns.

Mechanism of action

Salmonella bacteria invade the intestinal mucosa and evade the host's immune response. They utilize a type III secretion system to inject virulence factors into host cells, facilitating their entry and promoting inflammation. This invasion disrupts normal intestinal function, leading to diarrhea, abdominal pain, and systemic symptoms.

Pharmacodynamics

The pathogenicity of Salmonella is largely attributed to its ability to adhere to and invade host epithelial cells, triggering an inflammatory response. The bacteria can survive and replicate within macrophages, allowing them to disseminate systemically. The inflammatory response contributes to the clinical manifestations of the infection, including fever and diarrhea.

Pharmacokinetics

Salmonella does not have pharmacokinetics as it is a bacterial pathogen rather than a drug. However, the course of infection can be influenced by host factors, such as immune response and the presence of underlying health conditions. Antibiotic treatment may alter the natural course of infection and influence the duration and severity of symptoms.

Adverse effects

• Diarrhea
• Fever
• Abdominal cramps
• Nausea
• Vomiting

Precautions

• Ensure proper food handling and hygiene practices to prevent infection.
• Use caution in immunocompromised patients who may be at higher risk for severe disease.

Pregnancy

Salmonella infections during pregnancy can lead to complications such as miscarriage or premature labor. Caution is advised.

Breast-feeding

Salmonella can be transmitted through contaminated breast milk, though this is rare. Mothers should be cautious about food hygiene.

Indications

• Identification of bacterial and viral infections
• Epidemiological studies
• Vaccination strategies
• Clinical diagnostics

Dosage

Children: Refer to specific product guidelines or clinical protocols for dosing information as it varies based on the condition and serotype involved.

Adults: Refer to specific product guidelines or clinical protocols for dosing information as it varies based on the condition and serotype involved.

Mechanism of action

Serotyping involves the use of specific antibodies that bind to surface antigens of pathogens. This binding facilitates the identification and classification of serotypes based on their immunological properties. The immune response generated by these antigens can influence the severity of infections and the effectiveness of vaccines.

Pharmacodynamics

The pharmacodynamics of serotypes are not directly related to drug action but rather to the immune response they elicit. Different serotypes can cause varying degrees of virulence and influence host immune responses differently. The effectiveness of vaccines may also vary depending on the serotype, highlighting the importance of serotyping in vaccine development and epidemiology.

Pharmacokinetics

As serotypes are classifications based on antigenic properties rather than drugs, there are no pharmacokinetic profiles associated with them. However, understanding the pharmacokinetics of vaccines targeting specific serotypes is essential for assessing their efficacy and safety.

Pregnancy

Safety during pregnancy has not been established. Use only if potential benefits justify the risks.

Breast-feeding

Caution is advised. It is unknown whether this drug is excreted in human milk.

Storage

Store in a cool, dry place, protected from light. Follow specific manufacturer's instructions for storage conditions.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Dosage

Children: Refer to specific guidelines related to the underlying condition associated with the syndrome.

Adults: Refer to specific guidelines related to the underlying condition associated with the syndrome.

Pregnancy

Consult healthcare provider for advice as the safety of syndrome treatment during pregnancy depends on specific medication used and individual patient circumstances.

Breast-feeding

Consult healthcare provider for advice as the safety of syndrome treatment during breastfeeding depends on specific medication used and individual patient circumstances.

Storage

Store in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.